Discover 1,605 paid clinical trials in Newnan, Georgia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,605
A Beta-only IL-2 ImmunoTherapY Study
for
Advanced Solid Tumor, Unresectable Solid Tumor,
Location: Atlanta GA, Boca Raton FL, Detroit MI, Toronto,
Sponsor: Medicenna Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05086692
Phase1, Phase2, Recruiting
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
for
Metastatic Solid Tumor, Advanced Solid Tumor
Location: Atlanta GA, Greenville SC, Nashville TN, New Orleans LA,
Sponsor: Coherus Oncology, Inc.
Sex: All
Age: 18+
Code: NCT06657144
Phase1, Recruiting
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
for
Low-Grade Serous Ovarian Cancer
Location: Atlanta GA, Basking Ridge NJ, Middletown NJ,
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: Female
Age: 18+
Code: NCT06394804
Phase2, Recruiting
A Smoke-Free Home Intervention in Tribal Communities
for
Tobacco-Related Carcinoma
Location: Atlanta GA
Sponsor: Emory University
Sex: All
Age: 18+
Code: NCT06583148
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
for
Chronic Lymphocytic Leukemia (CLL),
Location: Atlanta GA, Durham NC, Cincinnati OH, Sarasota FL,
Sponsor: Nurix Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05131022
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Tumor Treating Fields for the Treatment of Brainstem Gliomas
for
Glioma
Location: Atlanta GA
Sponsor: Emory University
Sex: All
Age: 18+
Code: NCT05310448
Recruiting
Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer
for
Resectable Lung Non-Small Cell Carcinoma
Location: Atlanta GA
Sponsor: Emory University
Sex: All
Age: 18+
Code: NCT06008730
Phase2, Recruiting
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Location: Atlanta GA, Chapel Hill NC, Columbus OH, Boston MA
Sponsor: Christine Ryan
Sex: All
Age: 18+
Code: NCT06043674
Phase2, Recruiting
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
for
Recurrent Classic Hodgkin Lymphoma,
Location: Atlanta GA
Sponsor: Emory University
Sex: All
Age: 12+
Code: NCT05039073
Phase2, Recruiting
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
for
Prostatic Neoplasms, Castration-Resistant
Location: Atlanta GA, Knoxville TN, Jackson MS, Louisville KY,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT07225946
Phase3, Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
for
Multiple Myeloma, Smoldering Multiple Myeloma,
Location: Atlanta GA, Denver CO
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06768489
Phase1, Recruiting
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
for
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer,
Location: Atlanta GA, Louisville KY, Orange City FL, Clermont FL,
Sponsor: Inhibrx Biosciences, Inc
Sex: All
Age: 18+
Code: NCT04198766
Phase1, Phase2, Recruiting
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
for
Myeloproliferative Neoplasms
Location: Atlanta GA, Nashville TN, Columbus OH
Sponsor: Incyte Corporation
Sex: All
Age: 18+
Code: NCT07441694
Phase1, Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma